| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1708 | 2019 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 498 | 2021 |
| Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN L Paz-Ares, Y Chen, N Reinmuth, K Hotta, D Trukhin, G Statsenko, ... ESMO open 7 (2), 100408, 2022 | 197 | 2022 |
| CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... Lancet 394 (10212), 1929-1939, 2019 | 137 | 2019 |
| Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer MP Petrova, MI Eneva, JI Arabadjiev, NV Conev, EG Dimitrova, ... Bioscience trends 14 (1), 48-55, 2020 | 58 | 2020 |
| CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... Lancet Oncol 22 (1), 51-65, 2021 | 51 | 2021 |
| Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients NV Conev, IS Donev, AA Konsoulova-Kirova, TG Chervenkov, JK Kashlov, ... Bioscience trends 9 (6), 393-401, 2015 | 48 | 2015 |
| Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer MP Petrova, IS Donev, MA Radanova, MI Eneva, EG Dimitrova, ... Clinical & Experimental Immunology 202 (3), 353-362, 2020 | 38 | 2020 |
| RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer NV Conev, YK Kashlov, EG Dimitrova, YK Kashlov, MK Bogdanova, ... Clinical and Investigative Medicine 42 (1), E31-E38, 2019 | 34 | 2019 |
| Impact of brain metastases on treatment patterns and outcomes with first-line durvalumab plus platinum-etoposide in extensive-stage SCLC (CASPIAN): A brief report Y Chen, L Paz-Ares, N Reinmuth, MC Garassino, G Statsenko, ... JTO Clinical and Research Reports 3 (6), 100330, 2022 | 28 | 2022 |
| PL02.11 Overall Survival with Durvalumab plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Sudy L Paz-Ares, Y Chen, N Reinmuth, K Hotta, G Trukhin, J Statsenko, ... 2019 World Conference on Lung Cancer, 9, 2019 | 28 | 2019 |
| LBA61 Durvalumab±tremelimumab+ platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study L Paz-Ares, Y Chen, N Reinmuth, K Hotta, D Trukhin, G Statsenko, ... Annals of Oncology 32, S1338, 2021 | 25 | 2021 |
| LBA86 Durvalumab (D)±tremelimumab (T)+ platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN JW Goldman, MC Garassino, Y Chen, N Reinmuth, K Hotta, A Poltoratskiy, ... Annals of Oncology 31, S1212-S1213, 2020 | 25 | 2020 |
| Association between serum CK-18 levels and the degree of liver damage in fructose-induced metabolic syndrome K Bratoeva, S Nikolova, A Merdzhanova, GS Stoyanov, E Dimitrova, ... Metabolic syndrome and related disorders 16 (7), 350-357, 2018 | 22 | 2018 |
| First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes. Y Chen, LG Paz-Ares, M Dvorkin, D Trukhin, N Reinmuth, MC Garassino, ... Journal of Clinical Oncology 38 (15_suppl), 9068-9068, 2020 | 20 | 2020 |
| Durvalumab±Tremelimumab+ Platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden L Paz-Ares, MC Garassino, Y Chen, N Reinmuth, K Hotta, A Poltoratskiy, ... Clinical Cancer Research 30 (4), 824-835, 2024 | 17 | 2024 |
| Circulating histones to detect and monitor the progression of cancer DK Tsoneva, MN Ivanov, NV Conev, R Manev, DS Stoyanov, ... International journal of molecular sciences 24 (2), 942, 2023 | 17 | 2023 |
| Single nucleotide polymorphisms in microrna genes and colorectal cancer risk and prognosis M Radanova, M Levkova, G Mihaylova, R Manev, M Maneva, R Hadgiev, ... Biomedicines 10 (1), 156, 2022 | 16 | 2022 |
| New circulating circular RNAs with diagnostic and prognostic potential in advanced colorectal cancer M Radanova, G Mihaylova, O Tasinov, DP Ivanova, GS Stoyanov, ... International Journal of Molecular Sciences 22 (24), 13283, 2021 | 12 | 2021 |
| Rare case of ameloblastoma with pulmonary metastases I Valkadinov, N Conev, D Dzhenkov, I Donev Intractable & Rare Diseases Research 6 (3), 211-214, 2017 | 12 | 2017 |
Igor BondarenkoProfessor of Oncology, Dnipro State Medical University (Ukraine)Потвърден имейл адрес: dmu.edu.ua
